An epidemiological study linking PDZ-RhoGEF polymorphisms with lung cancer risk suggested that there were interactions between RGS2, RGS6, and PDZ-RhoGEF and validated this family of proteins as key regulators of tumorigenesis. This evidence concerns the gene ARHGEF11 and lung cancer.